newsfilter
← Latest News
GlobeNewswire·

BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,